Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a Buy.

The vaccine maker is expanding beyond its COVID-focused offerings.

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Moderna (MRNA) stock hits a 52-week high to extend its YTD rally following back-to-back years of declines. Read more here.

Moderna lowered the high end of its 2025 revenue outlook, citing a delay in vaccine shipments to the U.K. The company lost less than Wall Street analysts were expecting for the second quarter and ...

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.

Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, Moderna announced that promising clinical, safety, and translational data from ...

Cambridge, Massachusetts-based Moderna, Inc. (MRNA), a biotechnology company, discovers, develops, and commercializes ...